TROPHIMMUN: Avelumab for gestational trophoblastic tumours resistant to monochemotherapy

Bookmark and Share
Published: 5 Jun 2020
Views: 1110
Prof Benoit You - Hospices Civils de Lyon, Lyon, France

Prof Benoit You talks to ecancer in an online interview about the TROPHIMMUN phase II trial which he presented at the ASCO 2020 virtual meeting.

The TROPHIMMUN trial looks at avelumab in patients with gestational trophoblastic tumours resistant to monochemotherapy.

He outlines the background, trial design, results and toxicity profile.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.